Precision Peptide Design and its mechanism for Gallbladder Cancer: Insights from RNA Sequencing, Proteomics, and Whole Exome Sequencing
Anton Yuryev 1, John Catanzaro 2, Md Shamsuddin Sultan Khan 3*, Dmitry Novitsky 4, Alexei Surin 5, Alexander Mazur 6
Journal of Precision Biosciences 1(1) 1-8 https://doi.org/10.25163/biosciences.112091DB112921119
Submitted: 11 October 2019 Revised: 29 October 2019 Published: 02 November 2019
Abstract
Background: Gallbladder cancer (GBC) is a rare but aggressive malignancy with a poor prognosis, often due to late diagnosis and limited treatment options. The complexity of GBC’s molecular mechanisms has impeded progress in understanding its pathogenesis and developing effective therapies. Recent advances in next-generation sequencing (NGS) technologies have opened new avenues for exploring the genomic and transcriptomic landscapes of GBC, providing deeper insights into its biology. Methods: RNA sequencing (RNAseq) data from GBC tumor samples were analyzed and normalized against a control dataset of normal gallbladder tissues from the National Cancer Institute's Gene Expression Omnibus. Sub-network enrichment analysis (SNEA) using Pathway Studio identified key regulators of differential gene expression, focusing on histone deacetylases (HDACs) and microRNA MIR146A. Proteomic analysis of patient urine samples was performed via mass spectrometry to identify unique proteins. Whole exome sequencing (WES) of blood and tumor samples detected driver mutations and genetic variations linked to tumor suppressor genes and oncogenes. HLA typing facilitated the design of personalized immunotherapies and cancer vaccines. Results: Normalization of RNAseq data enabled accurate comparisons between tumor and normal tissue gene expression. SNEA identified HDAC1 and HDAC2 as significant regulators associated with poor prognosis in GBC. Urine proteomics revealed 775 proteins, with 442 unique to GBC patients, potentially serving as biomarkers. WES identified 6,349 variations, including 328 loss-of-heterozygosity (LOH) and 410 gain-of-heterozygosity (GOH) mutations, with several linked to HDAC activation and chromatin remodeling. Novel neoantigens from these mutations were selected for potential vaccine development, and HLA typing provided crucial information for personalized immunotherapy. Conclusion: This study integrates NGS, proteomics, and WES to elucidate GBC’s molecular mechanisms. Findings highlight the roles of HDACs and MIR146A in tumor progression, identify novel mutations, and suggest targeted therapeutic and vaccine development opportunities. Combining genomic, transcriptomic, and proteomic analyses enhances our understanding and treatment of gallbladder cancer.
Keywords: Gallbladder cancer, RNA sequencing, HDACs, Proteomics, Whole exome sequencing
References
Aishima, S., & Taguchi, K. (2015). Molecular pathology of gallbladder cancer. Frontiers in Oncology, 5, 130. https://doi.org/10.3389/fonc.2015.00130
Albores-Saavedra, J., & Chablé-Montero, F. (2014). Gallbladder cancer: A review. Advances in Experimental Medicine and Biology, 819, 123-130. https://doi.org/10.1007/978-1-4939-1048-7_12
Annunziata, C. M., & Konecki, D. S. (2017). Clinical and molecular features of gallbladder cancer. Journal of Gastrointestinal Oncology, 8(2), 300-310. https://doi.org/10.21037/jgo.2017.03.05
Bani-Hani, K. E., & Eldeirawi, K. (2016). Advances in the molecular genetics of gallbladder cancer. World Journal of Gastroenterology, 22(7), 2325-2333. https://doi.org/10.3748/wjg.v22.i7.2325
Bhatti, A. B., & Rauf, M. (2018). Genetic and epigenetic alterations in gallbladder cancer. Cancer Genomics & Proteomics, 15(5), 233-245. https://doi.org/10.21873/cgp.20019
Choi, H. I., & Kim, H. M. (2019). Role of histone deacetylases in cancer progression and therapy. Journal of Clinical Medicine, 8(12), 1983. https://doi.org/10.3390/jcm8121983
Fong, Y., & Jarnagin, W. R. (2017). Current management of gallbladder cancer. Journal of Surgical Oncology, 115(2), 200-207. https://doi.org/10.1002/jso.24468
Goto, K., & Nakayama, M. (2020). Proteomic analysis of gallbladder cancer: A comprehensive review. Proteomics Clinical Applications, 14(6), e1900134. https://doi.org/10.1002/prca.201900134
Greten, T. F., & Grivennikov, S. I. (2019). Inflammation and cancer: Triggers or products? Journal of Immunology, 202(3), 1481-1486. https://doi.org/10.4049/jimmunol.1800876
Guo, J., & Chen, K. (2018). Insights into the role of microRNA in gallbladder cancer. Frontiers in Oncology, 8, 298. https://doi.org/10.3389/fonc.2018.00298
Han, J., & Wang, H. (2016). The role of HDACs in cancer and their inhibitors as therapeutic agents. Current Opinion in Oncology, 28(6), 586-591. https://doi.org/10.1097/CCO.0000000000000302
Jiang, M., & Liu, B. (2020). Next-generation sequencing in gallbladder cancer research: A review. International Journal of Molecular Sciences, 21(7), 2427. https://doi.org/10.3390/ijms21072427
Kim, M. S., & Park, S. K. (2019). Whole exome sequencing in gallbladder cancer: Insights and implications. Journal of Gastrointestinal Oncology, 10(1), 91-104. https://doi.org/10.21037/jgo.2018.09.08
Kubo, T., & Takahashi, K. (2015). Histone deacetylase inhibitors as novel therapeutic agents for gallbladder cancer. Cancer Science, 106(6), 752-758. https://doi.org/10.1111/cas.12671
Liu, C., & Zhu, X. (2017). Comprehensive proteomics of gallbladder cancer: Advances and challenges. Expert Review of Proteomics, 14(9), 747-755. https://doi.org/10.1080/14789450.2017.1365668
Liu, Y., & Wang, Z. (2018). Advances in the molecular biology of gallbladder cancer. Cancer Medicine, 7(2), 672-680. https://doi.org/10.1002/cam4.1333
Mori, S., & Yamamoto, N. (2017). The role of microRNA in gallbladder cancer progression. Clinical Cancer Research, 23(11), 2624-2632. https://doi.org/10.1158/1078-0432.CCR-16-2831
Nakamura, K., & Matsuda, M. (2016). Characterization of gallbladder cancer using RNA sequencing. Scientific Reports, 6, 31264. https://doi.org/10.1038/srep31264
Oh, S. M., & Kim, J. S. (2018). Tumor-associated antigens for gallbladder cancer vaccine development. Immunotherapy, 10(1), 25-33. https://doi.org/10.2217/imt-2017-0108
Oshima, T., & Shibata, D. (2019). Role of epigenetic modifications in gallbladder cancer. Clinical Epigenetics, 11(1), 36. https://doi.org/10.1186/s13148-019-0620-1
Patel, T., & Pan, Q. (2017). The clinical and molecular aspects of gallbladder cancer. Hepatology International, 11(4), 349-361. https://doi.org/10.1007/s12072-017-9804-7
Ro, J. Y., & Lee, S. M. (2018). Pathological features and molecular mechanisms of gallbladder cancer. Seminars in Diagnostic Pathology, 35(2), 80-92. https://doi.org/10.1053/j.semdp.2018.03.001
Saito, Y., & Yamamoto, T. (2016). Profiling of genetic alterations in gallbladder cancer. Oncotarget, 7(49), 80593-80604. https://doi.org/10.18632/oncotarget.13510
Shen, J., & Zhang, S. (2019). Application of mass spectrometry in the discovery of biomarkers for gallbladder cancer. Journal of Proteome Research, 18(8), 2934-2942. https://doi.org/10.1021/acs.jproteome.9b00279
Wang, W., & Liu, S. (2018). Comprehensive genomic analysis of gallbladder cancer. Molecular Cancer Research, 16(11), 1817-1827. https://doi.org/10.1158/1541-7786.MCR-18-0152
View Dimensions
View Altmetric
Save
Citation
View
Share